Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results

Supportive Care in Cancer

Volumn 17, Issue 12, 2009, Pages 1469-1473

  Lorusso, V ^a   Spedicato, A ^a   Petrucelli, L ^a   Saracino, V ^a   Giampaglia, M ^a   Perrone, T ^b  

^a VITO FAZZI HOSPITAL   (Italy)

^b Italfarmaco SpA   (Italy)

Author keywords

Chemotherapy induced nausea and vomiting (CINV); Highly emetogenic chemotherapy (HEC); Palonosetron

Indexed keywords

CISPLATIN; DEXAMETHASONE; EPIRUBICIN; IFOSFAMIDE; PACLITAXEL; PALONOSETRON; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CALORIC INTAKE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FOOD INTAKE; HUMAN; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; SINGLE DRUG DOSE;

AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; EATING; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PROSPECTIVE STUDIES; QUINUCLIDINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 71349083991     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0611-9     Document Type: Article

References (12)

1. MS Aapro SM Grunberg GM Manikhas G Olivares T Suarez SA Tjulandin LF Bertoli F Yunus B Morrica F Lordick A Macciocchi 2006 A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann Oncol. 17 9 1441 1449 10.1093/annonc/mdl137 1:STN:280:DC%2BD28rktVensw%3D%3D 16766588 (Pubitemid 44400384)
2. MS Aapro 2007 Palonosetron as an anti-emetic and anti-nausea agent in oncology Ther Clin Risk Manag 3 6 1009 1020 18516316
3. F Bozzetti SCRINIO Working Group 2009 Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients Support Care Cancer 17 3 279 284 10.1007/s00520-008-0476-3 10.1007/s00520-008-0476-3 18581148
4. MM Caro A Laviano C Pichard 2007 Nutritional intervention and quality of life in adult oncology patients Clinic Nutr 26 289 301 10.1016/j.clnu.2007.01. 005 (Pubitemid 46760478)
5. P Eisenberg J Figueroa-Vadillo R Zamora V Charu J Hajdenberg A Cartmell A Macciocchi S Grunberg 99-04 Palonosetron Study Group 2003 Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 11 2473 2482 10.1002/cncr.11817 1:CAS:528:DC%2BD3sXpvFOrt70%3D 14635083 (Pubitemid 37466663)
6. R Gralla M Lichinitser S Van Der Vegt H Sleeboom J Mezger C Peschel G Tonini R Labianca A Macciocchi M Aapro 2003 Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann Oncol 14 10 1570 1577 10.1093/annonc/mdg417 1:STN:280:DC%2BD3svktlKitQ%3D%3D 14504060 (Pubitemid 37304615)
7. SM Grunberg JM Koeller 2003 Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis Expert Opin Pharmacother 4 12 2297 2303 10.1517/14656566.4.12.2297 1:CAS:528: DC%2BD3sXptlemu74%3D 14640928 (Pubitemid 37541242)
8. C Rojas M Stathis AG Thomas EB Massuda J Alt J Zhang E Rubenstein S Sebastiani S Cantoreggi SH Snyder B Slusher 2008 Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor Anesth Analg 107 2 469 478 10.1213/ane.0b013e318172fa74 1:CAS:528:DC%2BD1cXoslGktrc%3D 18633025
9. E Van Cutsem J Arends 2005 The causes and consequences of cancer-associated malnutrition Eur J Oncol Nurs 9 S51 S63 10.1016/j.ejon.2005. 09.007 16437758 (Pubitemid 41488128)
10. F Roila PJ Hesketh J Herrstedt 2006 Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference Ann Oncol 17 20 28 10.1093/annonc/mdj936 1:STN:280:DC%2BD28%2FkvVKmtQ%3D%3D 16314401
11. C de Moor RS Cunningham 2005 Improving the functional status of patients with cancer by more effectively preventing chemotherapy induced nausea and vomiting (CINV): a comparison of palonosetron (PALO) vs ondansetron (OND) or dolasetron (DOL) J Support Oncol 3 5 Suppl 3 25 26 PA-12.8
12. AIOM 2007, AIOM (Italian Association of Medical Oncology) guidelines for the treatment and prevention of neoplastic anorexia. Version December 2007.